Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Under Fed Conditions

This study has been completed.
Sponsor:
Information provided by:
Teva Pharmaceuticals USA
ClinicalTrials.gov Identifier:
NCT01282801
First received: January 24, 2011
Last updated: February 11, 2011
Last verified: February 2011

January 24, 2011
February 11, 2011
September 2002
October 2002   (final data collection date for primary outcome measure)
  • Cmax of Venlafaxine. [ Time Frame: Blood samples collected over a 36 hour period. ] [ Designated as safety issue: No ]
    Bioequivalence based on Venlafaxine Cmax (maximum observed concentration of drug substance in plasma).
  • AUC0-t of Venlafaxine. [ Time Frame: Blood samples collected over a 36 hour period. ] [ Designated as safety issue: No ]
    Bioequivalence based on Venlafaxine AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).
  • AUC0-inf of Venlafaxine. [ Time Frame: Blood samples collected over a 36 hour period. ] [ Designated as safety issue: No ]
    Bioequivalence based on Venlafaxine AUC0-inf (area under the concentration-time curve from time zero to infinity).
Same as current
Complete list of historical versions of study NCT01282801 on ClinicalTrials.gov Archive Site
  • Cmax of O-Desmethylvenlafaxine. [ Time Frame: Blood samples collected over a 36 hour period. ] [ Designated as safety issue: No ]
    Informational comparison of Cmax values for the metabolite O-Desmethylvenlafaxine.
  • AUC0-t of O-Desmethylvenlafaxine. [ Time Frame: Blood samples collected over a 36 hour period. ] [ Designated as safety issue: No ]
    Informational comparison of AUC0-t values for the metabolite O-Desmethylvenlafaxine.
  • AUC0-inf of O-Desmethylvenlafaxine. [ Time Frame: Blood samples collected over a 36 hour period. ] [ Designated as safety issue: No ]
    Informational comparison of AUC0-inf values for the metabolite O-Desmethylvenlafaxine.
Same as current
Not Provided
Not Provided
 
Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Under Fed Conditions
Randomized, 2-way Crossover, Bioequivalence Study of Venlafaxine Hydrochloride 150 mg Extended-Release Capsules and Effexor® XR 150 mg Extended-Release Capsules Administered as 1 x 150 mg Extended-Release Capsules in Healthy Subjects Under Fed Conditions.

The objective of this study was to compare the rate and extent of absorption of venlafaxine hydrochloride 150 mg extended-release capsules (test) versus Effexor® XR (reference) administered as 1 x 150 mg extended-release capsule under fed conditions.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Healthy
  • Drug: Venlafaxine Hydrochloride
    150 mg Extended-Release Capsule
  • Drug: Effexor® XR
    150 mg Extended-Release Capsule
    Other Name: Venlafaxine Hydrochloride (generic name)
  • Experimental: Investigational Test Product
    Venlafaxine Hydrochloride 150 mg Extended-Release Capsules
    Intervention: Drug: Venlafaxine Hydrochloride
  • Active Comparator: Reference Listed Drug
    Effexor® XR 150 mg Extended-Release Capsules
    Intervention: Drug: Effexor® XR
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
18
October 2002
October 2002   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Members of the community at large.
  • Subjects will be females and/or males, non-smokers, 18 years of age and older.
  • Female subjects will be post-menopausal or surgically sterilized.

Exclusion Criteria:

  • Clinically significant illnesses within 4 weeks of the administration of study medication.
  • Clinically significant surgery within 4 weeks prior to the administration of the study medication.
  • Any clinically significant abnormality found during medical screening.
  • Any history or presence of significant neurological, endocrinal, cardiovascular, pulmonary, hematologic, immunologic, psychiatric or metabolic disease.
  • History or presence of any clinically significant gastrointestinal pathology, unresolved gastrointestinal symptoms, liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of the drug.
  • Subjects with raised intra-ocular pressure or at risk of acute narrow angle glaucoma.
  • Subjects predisposed to bleeding of the skin and mucous membrane.
  • Subjects with a history of seizures.
  • Any reason which, in the opinion of the medical sub-investigator, would prevent the subject from participating in the study.
  • Abnormal laboratory tests judged clinically significant.
  • Positive urine drug screen at screening.
  • Positive testing for hepatitis B, hepatitis C, or HIV at screening.
  • ECG abnormalities (clinically significant) or vital sign abnormalities at screening.
  • Subjects with BMI > 30.0.
  • History of significant alcohol abuse within six months of screening visit or any indication of the regular use of more than fourteen units of alcohol per week (1 unit equals 150 mL of wine, 360 mL of beer, or 45 mL of alcohol 45%).
  • History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana) within 3 months of the screening visit or hard drugs (cocaine, PCP, crack) within 1 year of the screening visit.
  • Any food allergy, intolerance, restriction, or special diet that, in the opinion of the medical sub-investigator, contraindicates the subject's participation in the study.
  • History of allergic reactions to venlafaxine hydrochloride.
  • History of allergic reactions to heparin.
  • Use of any drugs know to induce or inhibit hepatic drug metabolism, use of an investigational drug, or participation in an investigational study within 30 days prior to administration of the study medication.
  • Use of prescription medication within 14 days prior to administration of the study medication or over-the-counter products within 7 days prior to the administration of study medication, except for topical products without systemic absorption.
  • Subjects who have had a depot injection or an implant of any drug 3 months prior to administration of the study medication.
  • Donation of plasma (500 mL) within 7 days of Period I dosing. Donation or loss of whole blood prior to administration of the study medication as follows:

    • less than 300 mL of whole blood within 30 days or
    • 300 mL to 500 mL of whole blood within 45 days or
    • more than 500 mL of whole blood within 56 days.
  • Positive alcohol breath test at screening.
  • Subjects who have used tobacco in any form within the 90 days preceding study drug administration.
  • Subjects who have consumed food or beverages containing grapefruit within 7 days prior to administration of the study medication.
  • Intolerance to venipunctures.
  • Additional exclusion criteria for females only:

    • Breastfeeding subjects.
    • Positive urine pregnancy test at screening.
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT01282801
02205
Not Provided
Associate Director, Biopharmaceutics, Teva Pharmaceuticals, USA
Teva Pharmaceuticals USA
Not Provided
Principal Investigator: Benoit Girard, M.D. Anapharm
Teva Pharmaceuticals USA
February 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP